Nominee Refuses She’d Defy Pressure From CDC Contenders
A CDC director nominee faced tough questions about political interference and whether she would defy pressure from th...
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,374 articlesA CDC director nominee faced tough questions about political interference and whether she would defy pressure from th...
Chinese memory-maker CXMT gears up for a high-profile $8.6 billion IPO, sparking renewed pressure on U.S. and Asian m...
When a quality stock slips from its peak, income-minded investors often see a signal to act. This guide explains why ...
Dream Finders Homes expands its leadership with Steve Fischer, a banking veteran, joining the board and audit committ...
Apple may be eyeing a breakthrough to reduce on-device memory needs, a move that could shake Micron and the broader m...
A mediated settlement ends a years-long dispute between NEXA Lending's CEO and its former partner, yielding full cont...
As investors eye fastenal (FAST) 2026 earnings, the focus is on demand cycles, margin resilience, and cash flow stren...
A surge in AI inference demands is reshaping Google Cloud’s economics, forcing investors to weigh faster growth again...
Investors are rotating into advertising agency stocks as digital channels drive measurable results. The top picks com...
Travel trends shifting—here’s it’s changing where guests stay, how long they visit, and what hosts can charge. This g...
As earnings season arrives, praxis medicines 2025 earnings offer a compelling snapshot of where the company stands. T...
Hims & Hers Health announces a major acquisition of Australian digital health firm Eucalyptus, valued at up to $1.15 ...